13 February 2023: The Federal Ministers give a final decision (positive with conditions) for this trial
Trial reference:
A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors